Complement activation in thrombotic thrombocytopenic purpura by Réti M et al.
ORIGINAL ARTICLE
Complement activation in thrombotic thrombocytopenic
purpura
M. R E´T I , * , 1 P . FARKAS , , 1 D . CSUKA, K . R A´ZS O´ , A´ . SCHLAMMADINGER , M. L . UDVARDY ,§
K . MADA´CH,– G. DOMJ A´N ,** C . BERECZK I , G. S . REUSZ , A. J . SZABO´ and Z . PROHA´SZKA§§
*Department of Hematology and Stem Cell Transplantation, St Istva´n and St La´szlo´ Hospital of Budapest; 3rd Department of Medicine,
Semmelweis University, Budapest; 2nd Department of Medicine, University of Debrecen, Debrecen; §Clinical Research Center, University of
Debrecen, Debrecen; –Department of Anaesthesiology and Intensive Therapy, Semmelweis University, Budapest; **1st Department of Internal
Medicine, Semmelweis University; Department of Pediatrics, University of Szeged, Szeged; 1st Department of Pediatrics, Semmelweis
University, Budapest; and §§Research Group of Inflammation Biology and Immunogenomics, HAS-SU, Budapest, Hungary
To cite this article: Re´ti M, Farkas P, Csuka D, Ra´zso´ K, Schlammadinger A´, Udvardy ML, Mada´ch K, Domja´n G, Bereczki C, Reusz GS, Szabo´ AJ,
Proha´szka Z. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 791–8.
Summary. Background: Ultra-large vonWillebrand factor and
deﬁciency of its cleaving protease are important factors in the
events leading to thrombotic microangiopathy; however, the
mechanisms involved are only partly understood. Whereas
pathological activation of the alternative complement pathway
is linked to atypical hemolytic uremic syndrome, the role of
complement activation in thrombotic thrombocytopenic pur-
pura (TTP) is unknown.The aimof this studywas to investigate
whether signs of complement activation are characteristic of
TTP. Patients and methods: Twenty-three patients with TTP
(18 women, median age 38 years) and 17 healthy controls (13
women, median age 38 years) were included. Complement
parameters (C3, Factors H, I, B and total alternative pathway
activity) together with complement activation fragments (C3a)
or complexes (C1rs-INH, C3bBbP, sC5b9) were measured by
ELISA or RID. ADAMTS13 activity and anti-ADAMTS13
inhibitory antibodies were measured by the VWF-FRET73
assay. Results: Increased levels of C3a, and SC5b9 were
observed in TTP during acute episodes, as compared with
healthy controls. Decreased complement C3 levels indicative of
complement consumption occurred in 15% of acute TTP
patients. Signiﬁcant decrease of complement activation prod-
ucts C3a and SC5b9 was observed during plasma exchange
(PEX). The sustained presence of anti-ADAMTS13 inhibitory
antibodies in complete remission was associated with increased
complement activation. Conclusion: These data document in
an observational study the presence of complement activation
in TTP. Further investigation is needed to determine its
potential pathogenetic signiﬁcance.
Keywords: ADAMTS13 inhibitor, complement activation,
TTP.
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life-threat-
ening disease characterized by microvascular platelet-rich
thrombi leading to multiple organ failure [1]. The main clinical
features are consumptive thrombocytopenia, microangiopathic
hemolytic anemia, neurological dysfunction, renal failure and
fever. The plasma of patients contains ultra-large von Wille-
brand factor (ULVWF) multimers at disease onset, which are
highly reactive with platelets. ULVWF multimers are secreted
into the plasma by endothelial cells and platelets and rapidly
processed into smaller and less reactive multimers by cleavage
of VWF-cleaving protease [2]. VWF-cleaving protease is the
13th member of the ADAMTS (a-disintegrin and metallopro-
teinase with thrombospondin type 1 motifs) family, ADAM-
TS13. Two mechanisms for deﬁciency of ADAMTS13 activity
have been identiﬁed: in the majority of TTP patients inhibitory
autoantibodies against ADAMTS13 are present [3], whereas in
about 10% of the patients mutations of the ADAMTS13 gene
cause congenital deﬁciency of the protease and result in a
familial, autosomal recessive form of TTP [4].
The functional deﬁciency of ADAMTS13 plays a substantial
role in the development of TTP, but its deﬁciency is not
sufﬁcient alone to cause TTP. Environmental factors and
genetic modiﬁers may contribute to the full-blown manifesta-
tion of the disease. As suggested earlier, genes encoding
proteins involved in the regulation of the coagulation cascade,
VWF, or platelet function, components of the endothelial
vessel surface or the complement system may be implicated in
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susceptibility to develop thrombotic microangiopathy [5].
Previous ﬁndings suggest that abnormalities of complement
activation may contribute to the development of thrombotic
microangiopathy in patients with ADAMTS13 deﬁciency.
Platelet-associated C3 was reported in patients with TTP [6],
and low levels of C3 (indicative of complement activation and
consumption) were also observed in four out of six patients
with acute ADAMTS13-deﬁcient TTP [7]. Ruiz-Torres [7]
documented for the ﬁrst time that complement initiated
neutrophil activation and endothelial injury may have a crucial
role in microvascular thrombosis in TTP patients with
congenital or acquired ADAMTS13 deﬁciency. In this study,
serum from patients with thrombotic microangiopathy was
shown to cause C3 and membrane attack complex deposition
and surface expression of P-selectin on the human microvas-
cular endothelial cell line. The same sera also stimulated
neutrophils to release reactive oxygen species and proteinases,
leading to endothelial cell damage. All of these effects were
abrogated by complement inactivation, conﬁrming the impor-
tant role of complement activation in TTP.
In line with these observations, some precipitating clinical
factors, such as infections and pregnancy, are potential triggers
of complement activation; however, most TTP patients present
without triggers. On the other hand, epidemiologic evidence of
an association between complement activation and TTP is
missing. In addition, the activating pathway(s) of, and clinical
factors associated with, complement activation in TTP are
unknown. Furthermore, no information on the effect of
plasma exchange on complement activation product levels in
patients with TTP is available so far.
Therefore, we hypothesized that complement activationmay
associate with acute, ADAMTS13-deﬁcient TTP and poten-
tially contribute to the development of thrombotic microangi-
opathy. Accordingly, the aim of the current study was to
formally investigate in a case-control design the association of
complement activation with acute TTP, to examine the
activation pathway(s) involved, and to assess whether comple-
ment activation products change during plasma exchange
therapy.
Materials and methods
Patients and definitions
Twenty-three patients with TTP were enrolled in this single-
research laboratory-based investigation providing diagnostic
services (ADAMTS13 and complement measurements) since
August 2007 for patients suspected of having HUS or TTP in
Hungary. The patient enrollment was closed in January 2011.
The following criteria were used to guide patient and sample
selection.
Diagnosis of TTP was based on one or more episodes of
Coombs-negative microangiopathic hemolytic anemia with
thrombocytopenia deﬁned as serum lactate dehydrogenase
(LDH) > 450 U L)1, fragmented erythrocytes in the periph-
eral blood smear and platelet count < 150 G L)1; only
patients with severely decreased ADAMTS13 activity levels
(< 5%) were included in this study. Patients with acute oligo-
anuric renal failure were excluded from the study. Hemato-
logical remission (HR) was determined when platelet counts
were > 150 G L)1 on two consecutive days without any sign
of hemolysis even if there were any neurological, renal or other
residual clinical symptoms, whereas complete remission (CR)
was established when platelet count remained above the lower
limit continuously for at least 1 month. Relapse was considered
if disease activity reappeared after 1 month of platelet count
continuously higher than 150 G L)1, and exacerbation was
considered if TTP reactivated within 1 month.
Blood samples taken during an acute TTP episode (before
the initiation of plasma exchange [PEX]-series, during PEX-
series (taken before the next plasma exchange), within 2 weeks
after stopping of PEX-series and also in CR) were available for
13 patients. The replacement ﬂuids were 5% human albumin
(30–50% of total volume of substitution ﬂuid) followed by
fresh frozen plasma (50–70% of total volume of substitution)
to reduce the number of donor expositions. In another 10 TTP
patients, samples taken only in complete remission were
available, at the time-point of our investigations 4/10 had
normal ADAMTS13 activity, but all of them had history of
ADAMTS13 deﬁciency with inhibitors.
Healthy controls (n = 17) were selected according to age
and gender from a consecutive series of healthy subjects
recruited in an outpatient department providing regular health
check-ups for healthy employees on a mandatory basis.
Twenty-three per cent of the control women had history of
pregnancy.
Blood samples (EDTA-anticoagulated plasma, sodium-cit-
rate anticoagulated plasma and native serum) were taken by
antecubital venipuncture or from a central catheter, and cells
and supernatant separated by centrifugation and shipped in
cooled packages ()20 C) to the research laboratory, where
aliquots were made and stored in ultrafreezers at < )70 C
until determinations.
Determination of the complement proteins and complement
activation products
Complement C3 (Roche Cobas Integra 800 (Tina-quant C3c
2. ver. Cat. No.: 3001938, reference range 0.9–1.8 g L)1), factor
I and factor B (radial immunodiffusion, reference range for
both, 70–130%) and factor H (sandwich-enzyme-linked immu-
nosorbent assay (ELISA), 127–447 mg L)1) levels and total
alternative pathway activity (Wieslab Comp AP330 kit, 70–
105%, Euro Diagnostica, Malmo¨, Sweden) were measured in
serum samples. Levels of fragments C3a (MicroVue C3a des-
arg EIA A031, mean of healthy controls 129.6 ng mL)1), C4d
(MicroVue C4d EIA, A008, mean + 2 SD range 0.7–
6.3 lg mL)1) and SC5b-9 (MicroVue SC5b-9 Plus EIA,
A020, mean of healthy controls 200 ng mL)1, SD 85) were
determined with commercial kits (Quidel, San Diego, CA,
USA) according to the manufacturers instructions in EDTA
plasma samples. Within- and between-run coefﬁcients of
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variations of the assays, as tested in our laboratory, were
< 5.5% or < 13.5%, respectively.
Measurement of the complement activation product C3bBbP
The concentration of C3bBbP was determined with ELISA
based on Cat et al. [8], with some modiﬁcations [9]. In brief:
plates (Nunc, Maxisorp F96, Nunc GmbH, Langenselbold,
Germany) were coated with 1:1000 diluted goat anti-human
properdin (Incstar Corporation, Incstar, Stillwater, MN,
USA) and after blocking 1:10 diluted EDTA-plasma samples
and standards (normal human serum activated with zymo-
san, 1:100–1:12 800 diluted) were applied and developed by
biotin-conjugated rabbit anti-human C3c (Dako, Dako
Glostrup, Denmark) and streptavidin-peroxidase conjugate
(Jackson Immunoresearch, UK; Jackson West Grove, PA,
USA). Concentrations are expressed in units per mL sample:
1000 units correspond to the C3bBbP-content of 1 mL 1:10
diluted, zymosan-treated normal human serum (considered as
full activation of alternative pathway). Typical values of
healthy adults are mean 3.4 U mL)1 and SD 1.03, and
within- and between-run CV% < 5% and < 15%, respec-
tively [9].
Measurement of C1rC1sC1-inh complex
The serum concentration of C1rC1sC1-inh was determined by
ELISA [8] as described, with some modiﬁcations [9]. In brief:
plates (Nunc, Maxisorp F96) were coated with 1:500 diluted
rabbit anti-human C1-inh (Dako), after blocking 1:200 diluted
EDTA-plasma samples and standards (normal human serum
activated with heat-aggregated IgG, 1:500–1:32 000 diluted)
were added, followed by 1:500 diluted goat anti-human C1s
(DiaSorin, DiaSorin Saluggia, Italy) developed by 1:1000
diluted peroxidase-conjugated rabbit anti-goat IgG (Jackson
Immunoresearch). Concentrations are expressed in units per
mL of sample; 1000 units correspond to the C1rC1sC1-inh-
content of 1 mL 1:500 diluted normal serum, treated with heat-
aggregated IgG (considered as full activation of classical
pathway). Typical healthy control values are mean
5.72 U mL)1 and SD 6.8; within- and between-run
CV% < 15% [9].
Determination of ADAMTS13 activity
The ﬂuorigenic substrate, FRETS-VWF73, was applied for the
determination of ADAMTS13 enzyme activity as described
[10]. Brieﬂy, citrated plasma was diluted 1:20 in assay buffer
(5 mM Bis-Tris, 25 mM CaCl2, 0.005% Tween 20, pH 6.0) and
mixed with 5 lM FRETS-VWF73 substrate solution (20 lL
each), in white 384-well plates. Fluorescence was measured at
37 C every 2 min for 1 h in a Chameleon microplate reader
(Hidex, Turku, Finland) equipped with a 340 nm excitation
and a 460 nm emission ﬁlter. The reaction rate was calculated
by linear regression analysis of ﬂuorescence over time. A 2-fold
dilution series of normal human plasma (mixed from citrated
plasma samples of 10 healthy blood donors) was applied as
standard curve, and 100% ADAMTS13 activity was set at the
reaction rate observed in the 1:20 diluted sample. The intra-
assay variation coefﬁcient was < 5%, and the inter-assay
CV% was 6–9% (measured at 60% and 100% activity levels).
The presence of anti-ADAMTS13 inhibitors was determined
by mixing one part of the patients sample with one part of
normal pooled plasma, incubation at 37 C for 2 h, and
measurement of ADAMTS13 activity of the sample. The
presence of ADAMTS13 inhibitors was considered if the
patients original sample had < 7% activity, and that of the
mixed sample was < 50%.
Statistical analysis
The continuous variables reported in this study showed
skewed distribution and according to the results of the
Shapiro–Willks test deviated from the normal distribution.
Therefore, for descriptive purposes the values of each
measurement are given as median and 25th–75th percentile
or as numbers (per cent) and non-parametric tests were used
for group comparisons; continuous variables between two
groups were compared with the Mann–Whitney U-test, for
three or more groups with the Kruskal–Wallis ANOVA by
ranks test, and for repeated measures with the Friedman test.
Dunns post-test was used for group comparisons after
analysis of variance. Pearsons correlation coefﬁcients were
calculated on log-transformed variables. Statistical analyses
were carried out using STATISTICA 7.0 (StatSoft Inc., Tulsa,
OK, USA), SPSS 13.01 (Apache Software Foundation,
Chicago, DW, USA) and GRAPHPAD Prism 4.03 (GraphPad
Softwares Inc., La Jolla, CA, USA) softwares. Two tailed P-
values were calculated and the signiﬁcance level was put at a
value of P < 0.050.
Results
Description of the patient cohort
Clinical characteristics of the patients and controls are
presented in Tables 1 and 2. Median age of the TTP patients
was 38 years (IQ range 31–44), whereas in the healthy control
group it was 38 (31–46) years. The ratio of women tomen (18/5
in patients and 13/4 in controls) was similar in patients and
controls, and the BMI values of the study groups were similar
(P > 0.05). On average, the ﬁrst TTP episode presented in our
patients at the age of 36 years, and there was a mean total
number of episodes of 2.0/patient present. As for treatment
regiment, taking all of the 47 episodes of the 23 patients into
account, the following medications were applied: corticoster-
oids 100%, cyclophosphamide 52%, acetylsalicylic acid 43%,
rituximab 22%, vincristine 30%, azathioprine 22%, intrave-
nous immunoglobulin 9%, Asasantin (dipyridamole + ace-
tylsalicylic acid) or Persantin (dipyridamole) 13%, LMWH
4%, and two patients received ticlopidine in 1996. Splenectomy
was carried out in three (13%) patients. Neurological signs
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(78%), abdominal complaints (39%) and renal function
deterioration (17%) accompanying the last (current) TTP
episode, were present in the patients, whereas 13% had
hematological symptoms only. All of the patients were screened
for autoantibodies against complement factor H, and none of
them was found to be positive. None of the patients has been
diagnosed according to the ARA criteria as having SLE,
antiphospholipid syndrome or any other systemic autoimmune
disorder, based on testing of antinuclear-, anti-dsDNA, anti-
cardiolipin autoantibodies, lupus anticoagulant and typical
clinical signs. Documented triggering factors antecedent to
acute TTP episodes were infrequent in this TTP cohort; only 2/
23 pregnancies, 1/23 missed abortion and sepsis and 3/23
infections were documented. For patients seen with acute TTP
episode a total of 15 (mean, 4–38, range) PEX sessions were
required to reach remission. All of the 10 patients seen only
during remission were previously successfully treated with
therapeutic plasma exchange during acute TTP episodes.
Complement activation in TTP
As presented in Table 2, complement protein C3, factor I and
alternative pathway activity levels were the same in the groups,
whereas factor B and factor H concentrations were higher in
TTP patients, signiﬁcantly in complete remission as compared
with healthy controls (P < 0.05). A decreased complement C3
level (< 0.9 g L)1), indicative of severe complement activation
and consumption, did occur in 2/13 acute patients (15%).
Complement activation products, characteristic of the clas-
sical/lectin pathway (C1rs-INH, C4d), alternative pathway
(C3bBbP), terminal pathway (SC5b-9) and all pathways (C3a)
were also measured in the patients. As presented in Table 2,
higher C3a and SC5b-9 levels were observed in TTP patients, as
compared with healthy controls, and this difference was
statistically signiﬁcant in patients with an acute TTP episode,
before the initiation of PEX (both P < 0.01). C1rs-INH
complex, alternative pathway activation product (C3bBbP)
and C4d levels were similar in the groups investigated.
Table 1 Clinical data of the 23 patients with thrombotic thrombocytopenic purpura
Registry
code Gender
Age at
ﬁrst
episode
First TTP
episode
Last TTP
episode
Total no.
of TTP
episodes
Severe
ADAMTS13
deﬁciency
with inhibitor
Therapy
(cumulative,
all episodes)
Clinical
symptoms
(current/last
episode)
No. of PEX
sessions
(current
episode)
Acute TTP patients
HUN1 W 26 2007 2010 3 Yes S, IVIG, Rit N 15
HUN15 M 55 2008 2008 1 Yes S, Cy Abd 10
HUN23 M 38 2008 2008 1 Yes S R, Abd 12
HUN56 W 40 2006 2010 2 Yes S, Cy, Asasantin,
LMWH
N 8
HUN62 W 17 1991 2009 4 Yes S, Cy, Persantin,
ASA
N, Abd 15
HUN68 M 43 2010 2010 1 Yes S, Cy N 19
HUN72 W 13 2010 2010 1 Yes S, Cy, Rit N, abd 15
HUN76 W 58 2010 2010 1 Yes S, Cy, ASA N 7
HUN85 W 49 2010 2010 1 Yes S, Cy, IVIG, ASA,
VCR, Rit
N 38
HUN86 W 42 2010 2010 1 Yes S, Cy, ASA N, Abd 9
HUN126 M 36 2010 2011 2 Yes S, Cy, Rit None 28
HUN127 W 30 2010 2010 1 Yes S, Rit N 9
HUN131 W 39 2006 2011 2 Yes S, ASA None 4
TTP patients in complete remission
HUN3 M 29 1999 2006 3 Yes S, PEX N NA
HUN28 W 35 2008 2008 1 Yes S, AZA, PEX N, R, Abd NA
HUN31 W 31 2008 2008 1 Yes S, PEX None NA
HUN53 W 35 1994 1998 2 Yes S, AZA, ASA,
Asasantin, PEX
N NA
HUN58 W 20 1983 2010 3 Yes S, Cy, AZA, VCR,
PEX, ASA, Spl
N NA
HUN65 W 21 1995 2002 6 Yes S, AZA, VCR,
ticlopidin (in 1995),
Spl, PEX
N, R, Abd NA
HUN70 W 44 2006 2006 1 Yes S, Cy, VCR, PEX N NA
HUN78 W 38 2001 2001 1 Yes S, VCR, ASA, PEX N, R, Abd NA
HUN89 M 19 1996 2003 4 Yes S,VCR, ticlopidin (in
1996), ASA, PEX
N NA
HUN115 W 41 2000 2006 4 Yes S,Cy, VCR, AZA,
ASA, Spl, PEX
N, Abd NA
Abd, abdominal complaints; ASA, low-dose acetylsalicilic acid; AZA, azathioprine; Cy, cyclophosphamide; N, neurological signs; PEX, plasma
exchange; R, renal function deterioration; S, corticosteroid; Spl, splenectomy; VCR, vincristine.
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The course of complement activation during PEX in TTP
patients
In Fig. 1, data are presented for the 13 acute TTP patients for
whom blood samples were available before, during and
after the PEX-series. According to the results of paired,
non-parametric analysis of variance, the complement activa-
tion product C3a and SC5b-9 levels signiﬁcantly declined
during the PEX-series (all P < 0.05). There was an immediate
decrease of C3a and SC5b-9 concentrations in samples taken
during a series of PEX sessions and/or right after stopping PEX
(all P < 0.05, Dunns post-test), and complement activation
products remained low during CR. If C3a and SC5b-9 levels
were analyzed in TTP patients and healthy controls together by
means of Kruskall–Wallis ANOVA the differences were signif-
icant (P = 0.002 for C3a and P = 0.033 for SC5b-9), and the
results of Dunns post-test showed that C3a (P < 0.01) and
SC5b-9 (P < 0.05) levels were signiﬁcantly higher in the
before PEX group as compared with healthy controls. The
decrease of these complement activation markers during and
right after PEX was characteristic for all 13 patients, and was
accompanied by an increase in platelet counts and achieving
hematological and complete remission (data not shown).
ADAMTS13 inhibitor as an initiating factor of complement
activation in TTP
ADAMTS13 inhibitor was present in all of our patients with
acute TTP before the initiation of the PEX-series, and
ADAMTS13 inhibitor turned out to be negative in eight of
these 13 patients after achieving complete remission. We
analyzed whether the disappearance of ADAMTS13 inhibitor
was associated with decline of complement activation product
levels during the PEX-series. As shown in Fig. 2, a clear decline
was observed for C4d, C3bBbP and C3a fragments in the
ADAMTS13 inhibitor-negative group, while in the inhibitor-
positive group these activation product levels did not decrease
or increase.
Initiating pathways of complement activation in TTP
The characteristic feature of complement activation in acute
TTP was the presence of activated C3 (C3a) and terminal
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Fig. 1. Changes of complement activation product levels in TTP patients
during a series of therapeutic plasma exchange. Results (median, IQ-range
and minimum-maximum values) of TTP patients with available pre-PEX
and follow-up samples (n = 13) are displayed. P-values of Friedman tests
are indicated, * indicates if P < 0.05 of Dunns post-test, as compared
with before PEX.
Table 2 Complement protein and activation product levels of the study groups
Parameter
Acute TTP, before
PEX-series, n = 13
TTP, complete
remission, n = 10
Healthy control,
n = 17
Kruskal–Wallis or
v2 test, P
Age at blood draw (years) 42 (32–46) 37 (29–45) 38 (31–46) 0.543
Gender (f/m) 9/4 9/1 13/4 0.346
BMI 25.7 (23.2–30.0) 27.2 (22.4–35.1) 24.5 (20.7–28.1) 0.271
Complement C3 (g L)1) 1.49 (1.14–1.90) 1.56 (1.46–2.12) 1.2 (1.06–1.45) 0.158
Alternative pathway activity (%) 96 (83–101) 94 (81–104) 83 (75–98) 0.551
Factor B (%) 114 (92–138) 127 (111–155)* 92 (77–111) 0.013
Factor I (%) 126 (101–146) 114 (106–130) 107 (81–122) 0.087
Factor H (mg L)1) 385 (283–538) 622 (401–697)* 301 (211–397) 0.032
C1r-C1s-C1INH (U mL)1) 8.81 (5.11–13.33) 4.51 (3.11–9.97) 7.18 (4.01–9.61) 0.224
C4d (mg L)1) 1.39 (3.16–4.48) 2.67 (1.78–3.57) 2.15 (1.46–3.80) 0.748
C3bBbP (U mL)1) 1.99 (1.34–6.80) 2.21 (1.59–3.31) 1.71 (1.32–2.99) 0.496
Anaphylatoxin C3a (ng mL)1) 195 (170–514)*** 133 (117–221) 103 (80–138) 0.001
SC5b-9 (ng mL)1) 301 (242–424)** 241 (216–330) 181 (141–283) 0.006
*p<0.05; **p<0.01; ***p<0.001.
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complement complex (SC5b-9). Therefore we searched for
associated clinical factors and biochemical markers by means
of correlation analysis. The analysis was limited to the 13
patients with acute TTP and with available samples before the
PEX-series. As shown in Table 3, a strong positive correlation
was observed between activation markers C4d (classical and
lectin pathways), C3bBbP (alternative pathway) and C3a or
SC5b-9, respectively. Furthermore, C4d and C3bBbP levels
also correlated with each other (r = 0.657, P = 0.015). The
levels of the classical pathway marker C1rs-INH showed a
weak, borderline correlation with C3a (r = 0.531, P = 0.061)
and C4d (r = 0.528, P = 0.064).
Discussion
Here we report that increased plasma levels of complement
activation products were associated with acute TTP, showed a
clear decrease when plasma exchange therapy was initiated,
and were accompanied by an increase in platelet numbers and
achieving clinical remission. Pathological over-activation with
consumption of complement factors was observed in 15% of
our acute ADAMTS13-deﬁcient TTP patients, and clear-cut
activation of the classical/lectin and alternative pathways with
initiation of the terminal pathway was obviously shown. The
sustained presence of ADAMTS13 inhibitor after acute TTP
was associated with constantly high levels of complement
activation product levels, including C4d, C3a and C3bBbP,
even after achieving clinical remission, while disappearance of
ADAMTS13 inhibitor was linked to decline of C4d and C3a
levels in complete remission, indicative of the low level
activation of classical/lectin pathways. Our results indicate
that the complex therapy of an acute TTP episode (PEX series
and immunosuppressive treatment) results in the disappearance
of ADAMTS13 inhibitors and also in the decrease of
complement activation.
Earlier Ruiz-Torres et al. [7], studying TMA patients with
congenital ADAMTS13 deﬁciency and patients with ADAM-
TS13 inhibitors, reported that four out of six patients (66%)
had moderately decreased C3 levels in the acute phase of the
disease, indicative of complement activation and consumption.
In our study we observed decreased C3 levels in 2/13 TTP
patients in the acute phase (Fig. 1). The lower frequency of C3
decrease in our cohort, as compared with the six patients with
TMA in the study of Ruiz-Torres, may be related to patient
selection, because we did not include patients with the
congenital form of TTP.
As TTP due to the presence of anti-ADAMTS13 inhibitors
can also be considered as an immune-complex disease, our
ﬁndings may represent an epiphenomenon of this process.
Indeed, the activation of the C3a and terminal pathway was,
rather weakly, linked to activation levels of the classical
pathway. Furthermore, the sustained presence of ADAMTS13
inhibitor in complete remission was also linked to increased
complement activation.
However, previous literature data and our current observa-
tions may also indicate that activation of complement plays a
pathogenic role in TTP due to ADAMTS13 deﬁciency with
inhibitors. According to the two-hit model, deﬁciency of
ADAMTS13 predisposes to microvascular thrombosis but
TTP supervenes only after a triggering event occurs. The nature
of these triggering events is poorly understood currently,
because the vast majority of TTP patients present without
obvious clinical triggers. Potential triggering events include
common infections and pregnancy, both known by their
endothelial cell activating ability with increased secretion of
ultra-large VWF and P-selectin expression. Interestingly,
infections and pregnancy may also induce activation of the
complement system. Soluble complement activation related
mediators, including anaphylatoxins and the terminal comple-
ment complex SC5b-9, may directly activate endothelial cells
[11,12], neutrophils [13,14] and platelets [15,16]. Indeed, plasma
of TTP patients was shown to induce apoptosis of endothelial
cells and platelets [17–20] and activation of neutrophils and
monocytes [21], leading to the formation of platelet-leukocyte
Table 3 Correlation between complement activation product concentrations in the samples of patients with acute TTP, before the initiation of PEX-series
(n = 13)
Variable C1r-C1s-C1-INH C4d Bb C3bBbP C3a
SC5b-9 0.183 (0.548)* 0.727 (0.017) )0.209 (0.493) 0.714 (0.006) 0.762 (0.003)
C3a 0.531 (0.061) 0.661 (0.014) 0.056 (0.854) 0.764 (0.002) –
C3bBbP 0.255 (0.401) 0.657 (0.015) )0.009 (0.975) – –
Bb 0.396 (0.181) 0.308 (0.307) – – –
C4d 0.528 (0.064) – – – –
*Pearson correlation coeﬃcients and P-values were calculated after log-transformation of the variables. Statistically signiﬁcant correlations are
marked in bold.
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Fig. 2. Changes (CR/acute) of complement activation product levels
measured before and after PEX-series, according to the ADAMTS13
inhibitor status in remission. All patients with acute TTP (n = 13) were
ADAMTS13 inhibitor positive before the initiation of PEX-series, those
who remained inhibitor positive after reaching complete remission are
marked as clear (n = 5), whereas those who became ADAMTS13
inhibitor negative are marked as grey (n = 8). P-values < 0.05 obtained
in Mann–Whitney tests are marked with asterisks, comparing inhibitor
negatives and positives.
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complexes [22]. Zwart et al. [23] showed that complement
binding to apoptotic cells occurs in human plasma, and that the
dominant mechanism involves classical pathway activation by
IgM. In addition, complement activation by direct C1q binding
to apoptotic blebs was also shown [24].
Several of our observations support the theory that
complement activation in acute TTP patients may be, at least
partly, initiated via the classical pathway by immune com-
plexes and/or apoptotic cells. A strong correlation between
C4d levels (indicative of classical and/or lectin pathway
activation) and C3a and SC5b-9 was observed (Table 3). In
addition, a sustained presence of ADAMTS13 inhibitors after
treatment of acute TTP was linked to high levels of C4d,
C3bBbP and C3a, indicating the presence of ongoing com-
plement activation through classical and alternative pathways
(Fig. 2). Moreover, in TTP patients in complete remission, the
presence of ADAMTS13 inhibitor was tendentiously related
to increased levels of C4d. It is known that ADAMTS13
inhibitors may belong to IgG (100%), IgA (21%) or IgM
(7%) classes [25] with all IgG subclasses occurring. The most
prevalent (23%) anti-ADAMTS13 IgG subclass combination
in the study of Ferrari et al. [25] was to have all (IgG1 to 4)
subclasses. The human immunoglobulin classes and IgG
subclasses differ in their ability to induce complement
activation: while IgG1 and 3 mainly initiate the classical
pathway through C1q, at high epitope density and antibody
excess IgG2 may initiate the alternative pathway like IgA [26].
Ferrari et al. [25,27] reported that 82–94% of the TTP
patients in the acute ﬁrst episode and 27–36% of patients with
recurrent episodes had either of the complement activating
IgG1, two or three, or IgA ADAMTS13 inhibitor; however,
the presence of IgA inhibitors was mainly linked to that of
IgG. Furthermore, it was recently also demonstrated by co-
immunoprecipitation that circulating ADAMTS13 with im-
munoglobulins (ADAMTS13-speciﬁc IgG-IC) was present in
a patient with refractory TTP, and the ADAMTS13-IgG-ICs
followed an inverse kinetics to both the free IgG anti-
ADAMTS13 autoantibody and ADAMTS13 activity [28]. It
was concluded in the study by Ferrari et al. [28], that
formation of ADAMTS13-speciﬁc immune complexes cap-
turing all freely available ADAMTS13 should be considered
in patients who are refractory to treatment. Although we did
not look directly for ADAMTS13 immune complexes in our
study, the observations on circulating ADAMTS13 immune
complexes [28] and our above results on the presence of
complement activation via the classical/lectin pathways,
especially in patients with sustained presence of ADAMTS13
inhibitors, together indicate that circulating ADAMTS13
immune complexes may initiate complement activation in
patients with TTP and contribute to the microangiopathic
process.
We acknowledge potential limitations of our study. TTP is a
rare disorder, and we were unable to enrol more patients in a
reasonable short time-frame allowing the correct analysis of
complement activation. Therefore, due to the low number of
patients some of the analyses presented here are underpowered,
andmay be inconclusive, and therefore some of the conclusions
have to be taken as preliminary, until independent conﬁrma-
tion is published. The study of patients with congenital
ADAMTS13 deﬁciency would have helped to ﬁnd out the
role of ADAMTS13 inhibitor more exactly, but unfortunately,
no such patients have been diagnosed in our centre until the
end of our study. Moreover, because ADAMTS13 deﬁciency
as a result of two heterozygous mutations (causing V88M and
G1239V changes) together with a heterozygous mutation
(causing an S890I change) in factor H of complement was
found previously in a family [29], screening of complement
genes previously associated with thrombotic microangiopathy
would have been informative in our cohort, in relation to
complement activation.
In conclusion, here we report the ﬁrst clinical evidence of
increased complement activation in acute TTP, and that
therapeutic plasma exchange signiﬁcantly decreased the levels
of proinﬂammatory and cell-injuring complement activation
products. Our data indicate that the classical/lectin and
alternative pathways may initiate the terminal pathway in
TTP. In addition, the sustained presence of ADAMTS13
inhibitors in CR is linked to higher complement activation
product levels C4d, C3bBbP andC3a, indicative of the ongoing
activation of the classical and alternative pathways. These data,
if conﬁrmed in other cohorts, may form the rationale for
application of speciﬁc therapeutics aimed at controlling com-
plement activation in TTP.
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